Clinical Cancer Research, Vol 3, Issue 11 1999-2004, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Effect of 13-cis-retinoic acid and alpha-interferon on transforming growth factor beta1 in patients with rising prostate-specific antigen

RS DiPaola, RE Weiss, KB Cummings, FM Kong, RL Jirtle, M Anscher, J Gallo, S Goodin, S Thompson, Z Rasheed, J Aisner and MB Todd
Departments of Medicine and Surgery, Division of Urology, University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School, New Brunswick, New Jersey 08903-0019, USA.

The objective of this study was to test the hypothesis that 13-cis-retinoic acid (CRA) and alpha-interferon (IFN-alpha) have antitumor activity in patients with early recurrence of prostate cancer measured by rising prostate-specific antigen (PSA) after local therapy, and that this activity is associated with the increase of plasma transforming growth factor beta1 (TGF-beta1). Thirty patients with a PSA > 7 ng/ml that increased >0.4 ng/ml/month after initial radiation therapy or a PSA > 2.0 ng/ml after prostatectomy were treated with 1 mg/kg/day of CRA and 3 million units of IFN-alpha administered three times per week. Patients were followed clinically with serum measurements of PSA and assessment of toxicity. Biological activity of CRA and IFN-alpha was assessed by the measurement of plasma TGF-beta1. Twenty-six percent of patients had a partial (50% decrease maintained for 1 month) or minimal (<50% decrease maintained for 1 month) biochemical response of PSA, with a median decrease of 23% (11-55%) at 3 months. Plasma TGF-beta1 levels increased with CRA and IFN-alpha therapy and correlated with a decrease in PSA; patients with a decrease in PSA had a 151% increase in TGF-beta1 compared to 27% in patients without a decrease in PSA (P = 0.04). CRA and IFN-alpha can produce transient reduction or stabilization of PSA. The measurement of plasma TGF-beta1 at 1 month of therapy correlates with changes in PSA and may represent a useful marker for the biological effect of these agents; further analysis in larger numbers of patients and methods to optimize these effects should be explored.

This article has been cited by other articles:

				X. Guo, B. S. Knudsen, D. M. Peehl, A. Ruiz, D. Bok, R. R. Rando, J. S. Rhim, D. M. Nanus, and L. J. Gudas Retinol Metabolism and Lecithin:Retinol Acyltransferase Levels Are Reduced in Cultured Human Prostate Cancer Cells and Tissue Specimens Cancer Res., March 1, 2002; 62(6): 1654 - 1661. [Abstract] [Full Text] [PDF]

				M. Shalev, T. C. Thompson, A. Frolov, S. M. Lippman, W. K. Hong, H. Fritsche, and D. Kadmon Effect of 13-cis-Retinoic Acid on Serum Prostate-specific Antigen Levels in Patients with Recurrent Prostate Cancer after Radical Prostatectomy Clin. Cancer Res., October 1, 2000; 6(10): 3845 - 3849. [Abstract] [Full Text]

				M. E. Cvijic, T. Kita, W. Shih, R. S. DiPaola, and K.-V. Chin Extracellular Catalytic Subunit Activity of the cAMP-dependent Protein Kinase in Prostate Cancer Clin. Cancer Res., June 1, 2000; 6(6): 2309 - 2317. [Abstract] [Full Text]

				W. K. Kelly, I. Osman, V. E. Reuter, T. Curley, W. D. W. Heston, D. M. Nanus, and H. I. Scher The Development of Biologic End Points in Patients Treated with Differentiation Agents: An Experience of Retinoids in Prostate Cancer Clin. Cancer Res., March 1, 2000; 6(3): 838 - 846. [Abstract] [Full Text]

				R. S. DiPaola, M. M. Rafi, V. Vyas, D. Toppmeyer, E. Rubin, J. Patel, S. Goodin, M. Medina, P. Medina, R. Zamek, et al. Phase I Clinical and Pharmacologic Study of 13-cis-Retinoic Acid, Interferon Alfa, and Paclitaxel in Patients With Prostate Cancer and Other Advanced Malignancies J. Clin. Oncol., July 1, 1999; 17(7): 2213 - 2213. [Abstract] [Full Text] [PDF]